Results 71 to 80 of about 3,601 (193)

Evidence of Pyrimethamine and Cycloguanil Analogues as Dual Inhibitors of Trypanosoma brucei Pteridine Reductase and Dihydrofolate Reductase

Pharmaceuticals, 2021
Trypanosoma and Leishmania parasites are the etiological agents of various threatening neglected tropical diseases (NTDs), including human African trypanosomiasis (HAT), Chagas disease, and various types of leishmaniasis.
Giusy Tassone, Giacomo Landi, Pasquale Linciano, Valeria Francesconi, Michele Tonelli, Lorenzo Tagliazucchi, Maria Paola Costi, Stefano Mangani, Cecilia Pozzi   +8 more
doaj   +1 more source

Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis [PDF]

, 2018
Interest in nitroheterocyclic drugs for the treatment of infectious diseases has undergone a resurgence in recent years. Here we review the current status of monocyclic and bicyclic nitroheterocyclic compounds as existing or potential new treatments for ...
Alan H. Fairlamb, Alliance T.B., Altcheh J., Andrade H.M., Andrade S.G., Andrade S.G., Andrews K.T., Ang C.W., Araldi R.P., Aubé J., Bahia M.T., Bahia M.T., Balasubramanian B., Barreto-Bergter E., Berriman M., Bisser S., Blumenstiel K., Boiani M., Brener Z., Bruhn D.F., Bustamante J.M., Campos M.C., Campos M.C., Chung M.C., Collins A.R., Darsaud A., de Andrade A.L., Deavall D.G., Dikhit M.R., Docampo R., Docampo R., Docampo R., Dodd M.C., Dogra M., El-Sayed N.M., Enanga B., Eperon G., Fabbro D.L., Fairlamb A.H., Fairlamb A.H., Fairlamb A.H., Fernández M.L., Ferreira R.C., Filardi L.S., Fonseca-Berzal C., Garavaglia P.A., Goijman S.G., Gupta S., Gurumurthy M., Hall B.S., Hall B.S., Hayashi M., Henderson G.B., Henderson G.B., Henriques C., Ivens A.C., Jacobs R.T., Janssens P.G., Jeganathan S., Jennings F.W., Kaiser M., Kubata B.K., Lewis M.D., Lewis M.D., Lewis M.D., Likeufack A.C.L., Maina N., Makarov V., Marin-Neto J.A., Marin-Neto J.A., Matsumoto M., Maya J.D., Mejia A.M., Mejía-Jaramillo A.M., Mesu V.K.B.K., Miura K., Moens F., Molina I., Moreno M., Moreno S.N.J., Morillo C.A., Morillo C.A., Mortelmans K., Mukherjee T., Mukkavilli R., Murta S.M., Murta S.M.F., Murta S.M.F., Neal R.A., Nesslany F., Nogoceke E., Nogueira F.B., Nogueira F.B., Olmo F., Panicucci R., Papadopoulou M.V., Papadopoulou M.V., Papadopoulou M.V., Patterson S., Patterson S., Patterson S., Portal P., Priotto G., Priotto G., Pépin J., Pépin J., Raether W., Repetto Y., Rodriques Coura J., Romero A.H., Ryan N.J., Sasahara K., Shimokawa Y., Singh R., Smith D.A., Sokolova A.Y., Stephen Patterson, Stover C.K., Stuart K., Tarleton R.L., Tarral A., Temperton N.J., Thompson A.M., Thompson A.M., Thompson A.M., Thompson A.M., Thompson A.M., Torreele E., Trochine A., Trochine A., Trunz B.B., Tweats D., Urbina J.A., Viodé C., Walsh J.S., Wilkinson S.R., Winkelmann E., Wyllie S., Wyllie S., Wyllie S., Wyllie S., Zhou L.   +141 more
core   +2 more sources

Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum

Pediatric Blood &Cancer, Volume 72, Issue 9, September 2025.
ABSTRACT High‐risk neuroblastoma is a poor prognosis cancer of the sympathetic nervous system that accounts for a disproportionate number of childhood cancer deaths. Many viable biological targets have been identified, and the number of potential combinations is even larger.
Steven G. DuBois, Lucas Moreno, John Anderson, Shahab Asgharzadeh, Ro Bagatell, Maja Beck‐Popovic, Jen Belle, Pablo Berlanga, Nick J. Bird, Louis Chesler, Adam Durbin, Angelika Eggert, Martin Eilers, Sara M. Federico, Matthias Fischer, Susanne A. Gatz, Rani E. George, Sally George, Kelly C. Goldsmith, Juliet Gray, Andras Heczey, Meredith S. Irwin, Leona Knox, Holger N. Lode, Donna Ludwinski, Margaret E. Macy, Robbie G. Majzner, John M. Maris, Shakeel Modak, Jan J. Molenaar, Daniel A. Morgenstern, Yael P. Mossé, Cormac Owens, C. Patrick Reynolds, Claudia Rossig, Gudrun Schleiermacher, Liz Scott, Paul M. Sondel, Frank Speleman, Max van Noesel, Frank Westermann, Judith Wienke, Adam J. Wolpaw, Julie R. Park, Andrew D. J. Pearson   +44 more
wiley   +1 more source

Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial

Bulletin of the World Health Organization, 2000
OBJECTIVE: A randomized controlled trial was conducted to determine whether 7 days of intravenous eflornithine (100 mg/kg every 6 h) was as effective as the standard 14-day regimen in the treatment of late-stage Trypanosoma brucei gambiense ...
Jacques Pépin, Nzambi Khonde, Faustine Maiso, Félix Doua, Shabbar Jaffar, Stéphane Ngampo, Bokelo Mpia, Dawson Mbulamberi, Felix Kuzoe   +8 more
doaj  

Adaptation and therapeutic exploitation of the plasma membrane of African trypanosomes [PDF]

, 2018
African trypanosomes are highly divergent from their metazoan hosts, and as part of adaptation to a parasitic life style have developed a unique endomembrane system.
Canavate Del Pino, Ricardo, Field, Mark, Quintana , Juan F., Yamada, Kayo, Zhang, Ning   +4 more
core   +3 more sources

Human African trypanosomiasis in two historical foci of the estuaire province, gabon: A case report

SAGE Open Medical Case Reports, 2020
Human African Trypanosomiasis (HAT) is an infectious disease due to a protozoa parasite of the Trypanosoma genus. In West and Central Africa, this disease is caused by the subspecies Trypanosoma brucei gambiense .
Berthe Amélie Iroungou, Larson Boundenga, Laurette Guignali Mangouka, Berthold Bivigou-Mboumba, Jean Raymond Nzenze, Gael Darren Maganga   +5 more
doaj   +1 more source

Investigation of Novel Isatinylhydantoin Derivatives as Potential Anti‐Kinetoplastid Agents

ChemMedChem, Volume 20, Issue 1, January 2, 2025.
A series of isatinylhydantoin derivatives were synthesized and investigated for antileishmanial and antitrypanosomal activities in vitro and in vivo. The derivative 5 was identified with higher leishmanicidal activity than the clinical drug amphotericin B while 4b was uncovered as in vitro trypanocidal hit against T. congolense parasite.
Keamogetswe Sechoaro, Janine Aucamp, Christina Kannigadu, Helena D. Janse van Rensburg, Keisuke Suganuma, David D. N'Da   +5 more
wiley   +1 more source

Exploration of Novel “Ferroxazide/Ferrazone” Derivatives as Antitrypanosomatid Agents: Design, Synthesis, and Biological Efficacy

Applied Organometallic Chemistry, Volume 39, Issue 1, January 2025.
A series of novel ferrocene derivatives, mimics of the clinical antibiotics, nifuroxazide and nitrofurazone, termed ferroxazides and ferrazones, respectively, were synthesized and evaluated for antitrypanosomatid activities. The ferroxazide 15 bearing dimethylamino moiety was identified in vitro as hit against Trypanosoma congolense strain but ...
Christina Kannigadu, Helena D. Janse van Rensburg, Janine Aucamp, Keisuke Suganuma, David D. N'Da   +4 more
wiley   +1 more source

Human African trypanosomiasis in endemic populations and travellers [PDF]

, 2018
Human African trypanosomiasis (HAT) or sleeping sickness is caused by the protozoan parasites Trypanosoma brucei (T.b.) gambiense (West African form) and T.b.
Blum, J., Hatz, C., Neumayr, A.
core  

Human colonic organoids for understanding early events of familial adenomatous polyposis pathogenesis

The Journal of Pathology, Volume 265, Issue 1, Page 26-40, January 2025.
Abstract Patients with familial adenomatous polyposis (FAP) harbor mutations in the APC gene and will develop adenoma and early colorectal cancer. There is no validated treatment, and animal models are not sufficient to study FAP. Our aim was to investigate the early events associated with FAP using the intestinal organoid model in a single‐center ...
Nolwenn Laborde, Alexandre Barusseaud, Muriel Quaranta, Corinne Rolland, Amélie Arrouy, Delphine Bonnet, Sylvain Kirzin, Nuria Sola‐Tapias, Dimitri Hamel, Karl Barange, Jean‐Pierre Duffas, Marie‐Pierre Gratacap, Julie Guillermet‐Guibert, Anne Breton, Nathalie Vergnolle, Laurent Alric, Audrey Ferrand, Frédérick Barreau, Claire Racaud‐Sultan, Emmanuel Mas   +19 more
wiley   +1 more source